Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged ≥18 years~* Last booster with a T-containing vaccine received 5 to 10 years prior to the administration of the study vaccine (documented by written evidence)~* Subject with vaccination history of a primary immunisation with a tetanus, diphtheria and poliomyelitis containing vaccine as recommended in the local vaccination calendar~* Negative urine pregnancy test for female subjects of child-bearing potential. A female subject who is of reproductive potential must agree to remain abstinent or use (or have her partner use) acceptable methods of birth control during the study period~* Subject having signed the informed consent form prior to participation in the study~Exclusion Criteria:~* Acute severe illness or fever (\>=38.0°C) within the last 3 days~* Hypersensitivity or known allergy to one of the components of one of the study vaccines (including formaldehyde, streptomycin, neomycin, polymyxin B, or glutaraldehyde)~* Anaphylactic or other allergic reactions to a previous dose of a vaccine containing diphtheria or tetanus toxoids or poliomyelitis viruses or pertussis (acellular or whole cell)~* Guillain Barré syndrome or neuropathy of brachial plexus following a previous vaccination with a tetanus toxoid containing vaccine~* Known encephalopathy after receipt of a pertussis vaccine or neurological disorders after an injection with the same antigens~* Progressive or unstable neurological disorder, uncontrolled seizures or progressive encephalopathy not stabilized~* Known malignant disease, note:~  * subjects with prostate or breast cancer who are not on chemotherapeutic drugs (other than hormone blocking drugs),~ * subjects with skin cancer who are not receiving radiation therapy or chemotherapy, and~ * subjects with a history of other malignancies who have been disease-free for at least 5 years will be eligible for enrollment~* Immunosuppressive therapy:~  * High dose (≥ 20 mg/day prednisone equivalent) systemic (≥ 14 days) corticosteroid treatment daily or on alternate day within the last 28 days (inhaled corticosteroids allowed)~ * Chemotherapeutic agents used to treat cancer or other conditions~ * Treatments associated with organ or bone marrow transplantation~* Immune dysfunction caused by a medical condition, or any other cause (e.g., congenital immunodeficiency, human immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma or generalized malignancy)~* Known severe thrombocytopenia or coagulation disorder contraindicating an intramuscular injection~* Administration of blood products including immunoglobulins within the last 90 days or planned before Visit 3~* Recent administration of a live vaccine (≤28 days) or an inactivated vaccine (≤14 days) or vaccination planned before Visit 3~* For female subjects, pregnancy (positive pregnancy test before first blood sample) or breast-feeding through Visit 3~* Planned participation in another clinical study during the present study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- REPEVAX (Type: EXPERIMENTAL): None
- Monovalent tetanus vaccine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).